ES2101079T3 - Marcadores analiticos para el cancer, principalmente para el cancer de seno. - Google Patents

Marcadores analiticos para el cancer, principalmente para el cancer de seno.

Info

Publication number
ES2101079T3
ES2101079T3 ES92901155T ES92901155T ES2101079T3 ES 2101079 T3 ES2101079 T3 ES 2101079T3 ES 92901155 T ES92901155 T ES 92901155T ES 92901155 T ES92901155 T ES 92901155T ES 2101079 T3 ES2101079 T3 ES 2101079T3
Authority
ES
Spain
Prior art keywords
cancer
mainly
breast cancer
understands
analytical markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901155T
Other languages
English (en)
Inventor
Paul Basset
Jean-Pierre Bellocq
Pierre Chambon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2101079T3 publication Critical patent/ES2101079T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN GEN QUE CODIFICA UN NUEVO ELEMENTO DE LA FAMILIA DE LAS METALOPROTEINAS QUE HA SIDO DESCUBIERTO POR ESTAR ESPECIFICAMENTE ASOCIADO AL CANCER DE MAMA INVASIVO, ASI COMO A PROCESOS DE DIAGNOSTICO PARA TAL CANCER QUE COMPRENDE LA DETECCION DEL MARCADOR O DE SU SECUENCIA NUCLEOTIDICA, Y AL TRATAMIENTO O LA PROFILAXIS POR INHIBICION, EN PARTICULAR, MODIFICACION DE LA ACTIVIDAD O ENLACE DEL MARCADOR, O POR PERTURBACION DE SU SINTESIS.
ES92901155T 1990-11-21 1991-11-21 Marcadores analiticos para el cancer, principalmente para el cancer de seno. Expired - Lifetime ES2101079T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9025326A GB2250993B (en) 1990-11-21 1990-11-21 Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer

Publications (1)

Publication Number Publication Date
ES2101079T3 true ES2101079T3 (es) 1997-07-01

Family

ID=10685753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901155T Expired - Lifetime ES2101079T3 (es) 1990-11-21 1991-11-21 Marcadores analiticos para el cancer, principalmente para el cancer de seno.

Country Status (16)

Country Link
US (1) US5236844A (es)
EP (1) EP0513316B1 (es)
JP (1) JP3516448B2 (es)
AT (1) ATE152179T1 (es)
CA (1) CA2073860A1 (es)
DE (1) DE69125824T2 (es)
DK (1) DK0513316T3 (es)
ES (1) ES2101079T3 (es)
GB (1) GB2250993B (es)
GR (1) GR3023560T3 (es)
HU (1) HU215165B (es)
IE (1) IE914056A1 (es)
NZ (2) NZ240688A (es)
PT (1) PT99562B (es)
WO (1) WO1992009701A1 (es)
ZA (1) ZA919219B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012645A2 (en) * 1992-11-25 1994-06-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
WO1995003428A1 (en) * 1993-07-20 1995-02-02 University Of Massachusetts Medical Center In vivo nucleic acid hybridization method
US6825024B1 (en) 1993-11-30 2004-11-30 Fuji Yakuhin Kogyo Kabushiki Kaisha Metalloproteinase and encoding DNA therefor
EP0685557B1 (en) * 1993-11-30 1998-08-12 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same
JPH07303482A (ja) 1993-11-30 1995-11-21 Fuji Yakuhin Kogyo Kk 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5710001A (en) * 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5763415A (en) 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5883241A (en) * 1995-09-05 1999-03-16 Celltech Therapeutics Limited DNA sequences coding for a human metalloproteinase and variants thereof
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
ATE331786T1 (de) * 1996-04-25 2006-07-15 Takeda Pharmaceutical Matrix-metalloprotease
DE69737788T2 (de) * 1996-10-31 2008-03-13 Abbott Laboratories, Abbott Park Reagenzien und methoden zum nachweis von erkrankungen der brust
US20050202499A1 (en) * 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US20050153373A1 (en) * 1996-10-31 2005-07-14 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US20030165971A1 (en) * 1996-10-31 2003-09-04 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
WO1998024935A1 (en) * 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
WO1998040475A1 (en) * 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
EP0969868A2 (en) 1997-03-18 2000-01-12 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for treating and diagnosing leiomyomas
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
US20040072210A1 (en) * 1997-07-07 2004-04-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
WO1999002714A1 (en) * 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2309756A1 (en) * 1997-11-17 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US20040219551A1 (en) * 2001-07-09 2004-11-04 Petersen Ole William Epsti1, a novel gene induced by epithelial-stromal interaction in human breast cancer
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US20050193432A1 (en) * 2003-11-18 2005-09-01 Whitehead Institute For Biomedical Research Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof
US7667001B1 (en) * 2004-01-27 2010-02-23 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US7569662B2 (en) * 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US20090191543A1 (en) * 2005-05-27 2009-07-30 Theregents Of The University Of California Identification of rac1b as a marker and mediator of metalloproteinase-induced malignancy
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CN106957356B (zh) 2010-05-11 2021-05-25 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
RU2015126650A (ru) 2012-12-10 2017-01-12 Фред Хатчинсон Кэнсер Рисёрч Сентер Партнеры липокалина по слиянию
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269724A1 (en) * 1986-06-17 1988-06-08 Celltech Limited Process for the production of a protein

Also Published As

Publication number Publication date
IE914056A1 (en) 1992-06-03
HU215165B (hu) 1998-10-28
AU9089691A (en) 1992-06-25
PT99562B (pt) 1999-04-30
EP0513316A1 (fr) 1992-11-19
GB2250993B (en) 1995-02-15
CA2073860A1 (en) 1992-05-22
AU646914B2 (en) 1994-03-10
DE69125824D1 (de) 1997-05-28
EP0513316B1 (fr) 1997-04-23
ATE152179T1 (de) 1997-05-15
PT99562A (pt) 1992-10-30
GR3023560T3 (en) 1997-08-29
WO1992009701A1 (fr) 1992-06-11
HUT65373A (en) 1994-05-02
JP3516448B2 (ja) 2004-04-05
GB2250993A (en) 1992-06-24
JPH05505530A (ja) 1993-08-19
ZA919219B (en) 1992-10-28
US5236844A (en) 1993-08-17
DE69125824T2 (de) 1997-08-07
HU9202368D0 (en) 1992-10-28
GB9025326D0 (en) 1991-01-02
NZ260705A (en) 1997-05-26
NZ240688A (en) 1994-09-27
DK0513316T3 (da) 1997-05-20

Similar Documents

Publication Publication Date Title
ES2101079T3 (es) Marcadores analiticos para el cancer, principalmente para el cancer de seno.
GT200200014A (es) Inhibidores de piridina de metaloproteinasas de la matriz
HRP20130707T1 (en) Compositions and uses for treating multiple sclerosis
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
BR112015022913A2 (pt) poliuretano, artigos e revestimentos preparados do mesmo e métodos para preparar os mesmos
AR019175A1 (es) Acero de cementacion a temperatura de revenido elevada, procedimiento de fabricacion de piezas cementadas y tratadas de dicho acero y piezas formadas con ese acero.
PA8799401A1 (es) Uso de un beta bloqueante para la fabricacion de un medicamento para el tratamiento de los hemangiomas
AR030816A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
BR112013012795B8 (pt) processo de tratamento de produtos vegetais e composição
MX9307232A (es) Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion.
CL2021001488A1 (es) Transposasa de piggybac mutada
AR045144A1 (es) Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo
AR117834A1 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis
BR0107928A (pt) Métodos para aumentar a saúde da planta, proteger as plantas de lesões relacionadas ao estresse biótico e estresse abiótico e aumentar a recuperação de plantas lesionadas como consequência de tais estresses
BR0208019A (pt) Fluoralcoxifenilsulfoniluréias substituìdas
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
AR013760A1 (es) Oligonucleotidos antisentido contra tenascina para el tratamiento de vitiligo.
BR112016029512A2 (pt) composição amaciante de tecido compreendendo um espessante heur
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
MX2022012637A (es) Secuencias antisentido para el tratamiento de esclerosis lateral amiotrofica.
BR112021017635A2 (pt) Composições e métodos para tratar a doença de huntington
ES2156319T3 (es) Derivados de 10,11-dihidro-10-oxo-5h-dibenz/b,f/azepin-5-carboxamida.
ES2060879T3 (es) Policarbonatos que contienen absorbentes de uv.
ES2154185B1 (es) Derivados clovanicos 2-o, 9 sustituidos y su preparacion, para el tratamiento de infecciones producidas por hongos fitopatogenos, como agentes fungiestaticos de bajo impacto ecologico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513316

Country of ref document: ES